<DOC>
	<DOC>NCT00765115</DOC>
	<brief_summary>To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta in lumbar cerebrospinal fluid from LY450139 treated subjects compared with placebo treated subjects.</brief_summary>
	<brief_title>A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy volunteers: Men within the ages of 21 and 50 Have serious or unstable medical conditions Have a history of serious infections affecting the brain or head trauma resulting in protracted loss of consciousness within the last 5 years or multiple episodes of head trauma Have a history of primary or recurrent malignant disease Have a recent laboratory result indicating a clinically significant laboratory abnormality as determined by the investigator Have a history of chronic alcohol or drug abuse within the past 5 years Have a known history of Human immunodeficiency virus (HIV), afebrile seizures, or clinically significant multiple drug allergies Are judged clinically by the investigator to be at serious risk for suicide Have electrocardiogram abnormalities obtained at visit 1 that in the opinion of the investigator are clinically significant Use of prescription or over the counter medications that cannot safely be discontinued within 14 days prior to visit 2 Have criteria that would preclude a LP such as allergy to all local anesthetics; have a local infection at the site of the LP or have any medical condition requiring treatment with warfarin or heparin. Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Are investigator site personnel directly affiliated with this study and or immediate families. Are Lilly employees</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>